NasdaqGS:DFTXPharmaceuticals
Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120
Definium Therapeutics (NasdaqGS:DFTX) reported positive topline Phase 3 results for DT120 in major depressive disorder.
The company completed a US$700 million follow on equity offering to fund regulatory and commercialization plans for DT120.
The latest data readout and capital raise were announced together as Definium Therapeutics positions DT120 for potential market entry.
Definium Therapeutics focuses on treatments for psychiatric conditions, with DT120 targeting major depressive...